Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Molecular signatures of antibody responses derived from a systems biology study of five human vaccines.

Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson SE, Milton A, Rajam G, Kasturi S, Carlone GM, Quinn C, Chaussabel D, Palucka AK, Mulligan MJ, Ahmed R, Stephens DS, Nakaya HI, Pulendran B.

Nat Immunol. 2014 Feb;15(2):195-204. doi: 10.1038/ni.2789. Epub 2013 Dec 15.

3.

Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.

Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Hlavata LC, Forleo-Neto E, Dagnew AF, Arora AK.

J Travel Med. 2015 Jan-Feb;22(1):48-56. doi: 10.1111/jtm.12164. Epub 2014 Oct 13.

4.

Strength in numbers: comparing vaccine signatures the modular way.

Haining WN.

Nat Immunol. 2014 Feb;15(2):139-41. doi: 10.1038/ni.2807. No abstract available.

PMID:
24448573
5.

Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Croxtall JD, Dhillon S.

Drugs. 2012 Dec 24;72(18):2407-30. doi: 10.2165/11209580-000000000-00000. Review.

PMID:
23231026
6.

MenACWY-TT vaccine for active immunization against invasive meningococcal disease.

Papaevangelou V, Spyridis N.

Expert Rev Vaccines. 2012 May;11(5):523-37. doi: 10.1586/erv.12.32. Review.

PMID:
22827239
7.

Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.

Wyplosz B, Derradji O, Hong E, François H, Durrbach A, Duclos-Vallée JC, Samuel D, Escaut L, Launay O, Vittecoq D, Taha MK.

Transpl Infect Dis. 2015 Apr;17(2):322-7. doi: 10.1111/tid.12359. Epub 2015 Mar 6.

PMID:
25645691
8.

Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.

Lieberman JM, Chiu SS, Wong VK, Partidge S, Chang SJ, Chiu CY, Gheesling LL, Carlone GM, Ward JI.

JAMA. 1996 May 15;275(19):1499-503.

PMID:
8622225
9.

Meningococcal conjugate vaccines.

Pichichero ME.

Expert Opin Biol Ther. 2005 Nov;5(11):1475-89. Review.

PMID:
16255651
10.

Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants.

Zhang Q, Pettitt E, Burkinshaw R, Race G, Shaw L, Finn A.

Pediatr Infect Dis J. 2002 Mar;21(3):209-13.

PMID:
12005084
11.

Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine?

MacDonald NE, Halperin SA, Law BJ, Danzig LE, Granoff DM.

JAMA. 2000 Apr 12;283(14):1826-7. No abstract available.

PMID:
10770143
12.

[Meningococcal vaccines: from polysaccharide to conjugate vaccines].

Cohen R, Levy C.

Arch Pediatr. 2012 Sep;19 Suppl 2:S61-4. doi: 10.1016/S0929-693X(12)71275-7. French.

PMID:
22883368
13.

Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.

Tunheim G, Arnemo M, Næss LM, Fjeldheim ÅK, Nome L, Bolstad K, Aase A, Mandiarote A, González H, González D, García L, Cardoso D, Norheim G, Rosenqvist E.

Vaccine. 2013 Dec 9;31(51):6097-106. doi: 10.1016/j.vaccine.2013.09.044. Epub 2013 Oct 10.

PMID:
24120679
14.

Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.

Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM.

J Infect Dis. 2006 Mar 15;193(6):821-8. Epub 2006 Feb 8.

PMID:
16479517
15.

Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.

Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M.

Pediatr Infect Dis J. 2015 Nov;34(11):1236-43. doi: 10.1097/INF.0000000000000866.

PMID:
26237742
16.

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.

MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM.

JAMA. 1998 Nov 18;280(19):1685-9.

PMID:
9832000
17.

Challenges for development of meningococcal vaccines in infants and children.

Deasy A, Read RC.

Expert Rev Vaccines. 2011 Mar;10(3):335-43. doi: 10.1586/erv.11.3. Review.

PMID:
21434801
18.

Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children.

Joseph H, Ryall R, Bybel M, Papa T, MacLennan J, Buttery J, Borrow R.

J Infect Dis. 2003 Apr 1;187(7):1142-6. Epub 2003 Mar 13.

PMID:
12660929
19.

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.

Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I.

Vaccine. 2015 May 15;33(21):2500-10. doi: 10.1016/j.vaccine.2015.03.001. Epub 2015 Mar 17.

PMID:
25795256
20.

Development of vaccines against meningococcal disease.

Jódar L, Feavers IM, Salisbury D, Granoff DM.

Lancet. 2002 Apr 27;359(9316):1499-508. Review.

PMID:
11988262

Supplemental Content

Support Center